© Yulia Lazarova
Learn the most important and interesting with the bulletin at 5 p.m. Every day, directly to your email.
The Association of University Hospitals issued a statement demanding an urgent legislative change to “avoid the real risk of obstructing the normal functioning of the health care system”, reports BTA.
The opinion is in connection with the draft “Methodology for the terms and conditions for payment by the National Health Insurance Fund (NHIF) of medicinal products administered in hospital medical care, outside the price of the relevant clinical pathways/ambulatory procedures”, published on the website of the NHIF.
Minister Hinkov: The re-export of medicines is the main problem of the healthcare system
According to the association, which represents 26 university hospitals, the rule introduced by the methodology – when there are no valid framework agreements for the previous year, the NHIF should pay the medicinal products at a price equal to the lowest price per unit quantity of medicinal substance for the same medicinal product from those supplied to all , who concluded a contract with the National Health Insurance Fund for hospital medical care contractors in the month preceding the month to which the medical institution’s report refers, will lead to over-indebtedness and bankruptcy of a number of medical institutions.
The Association of University Hospitals maintains its opinion that, when there are no valid framework agreements, medicinal products used in hospital medical care, which are paid by the NHIF outside the value of the medical services provided, should be paid at the value at which the medical institution purchased the specific medicinal product, but not higher than that specified in Appendix No. 2 of the Positive Medicinal List under the Law on Medicinal Products in Human Medicine.
On Wednesday (September 27), in an open letter from the Bulgarian Medical Union (BLS), they warned that the proposed methodology could increase the indebtedness of medical institutions and leave thousands of cancer patients without life-saving drugs. In the letter, they state that the risks of putting the new rule into effect are serious and range from generating losses for bona fide medical facilities that have purchased and administered medicinal products in compliance with current legislation, to blocking the supply of certain medicinal products and depriving thousands of cancer patients from life-saving drugs.